IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod. IMVT-1402 missed its main goal in a cutaneous lupus study in September, and that program was dropped. H.C. Wainwright termed Argenx’s trial halt in Sjögren’s a “surprising setback.” Wainwright said it is now more cautious … Read more